L Brewer1, S Rogers. 1. City of Dublin Skin and Cancer Hospital, Dublin, Ireland. lbrewer2004@yahoo.co.uk
Abstract
BACKGROUND: Fumaric acid esters (FAEs) offer an effective alternative to patients with psoriasis in whom other systemic agents are contraindicated or have failed. OBJECTIVE: We assessed the efficacy and side effect profile of FAEs in a group of patients with psoriasis. METHODS: A retrospective study was carried out on patients treated with FAEs over 21 months. Information was gathered from patients' notes. Dosage, response and side effects were recorded. RESULTS: In total, 31 patients were included. The mean age was 46.8 years. All patients had been treated with other modalities and 61.5% had received previous systemic treatment. There was good to excellent response in 58.6% of patients. Subjective side-effects were common (87.1%), and lymphopenia occurred in 61.3%. The drug was not tolerated by one-fifth of patients. CONCLUSION: The relatively low toxicity and absence of hepatotoxicity makes FAEs a reasonable first-line systemic treatment in selected patients with difficult psoriasis.
BACKGROUND:Fumaric acid esters (FAEs) offer an effective alternative to patients with psoriasis in whom other systemic agents are contraindicated or have failed. OBJECTIVE: We assessed the efficacy and side effect profile of FAEs in a group of patients with psoriasis. METHODS: A retrospective study was carried out on patients treated with FAEs over 21 months. Information was gathered from patients' notes. Dosage, response and side effects were recorded. RESULTS: In total, 31 patients were included. The mean age was 46.8 years. All patients had been treated with other modalities and 61.5% had received previous systemic treatment. There was good to excellent response in 58.6% of patients. Subjective side-effects were common (87.1%), and lymphopenia occurred in 61.3%. The drug was not tolerated by one-fifth of patients. CONCLUSION: The relatively low toxicity and absence of hepatotoxicity makes FAEs a reasonable first-line systemic treatment in selected patients with difficult psoriasis.
Authors: Tetsuo Toyama; Agnieszka P Looney; Brendon M Baker; Lukasz Stawski; Paul Haines; Robert Simms; Aleksander D Szymaniak; Xaralabos Varelas; Maria Trojanowska Journal: J Invest Dermatol Date: 2017-09-01 Impact factor: 8.551
Authors: Kyonghwan Choe; Hyun Young Park; Muhammad Ikram; Hyeon Jin Lee; Tae Ju Park; Rahat Ullah; Myeong Ok Kim Journal: Cells Date: 2022-04-11 Impact factor: 7.666
Authors: K Reich; M Augustin; D Thaçi; A Pinter; A Leutz; C Henneges; E Schneider; A Schacht; M Dossenbach; U Mrowietz Journal: Br J Dermatol Date: 2019-11-19 Impact factor: 9.302